KUALA LUMPUR, Oct 23 (Bernama) -- Recursion, a clinical stage TechBio company, announced the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral ...

SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient ...

Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 results, ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has seen significant share price volatility in 2025, dropping 27% year-to-date and trading over 55% below its 52-week high of $12. Despite this underperformance ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks on Jim Cramer’s radar recently. When a caller asked about ...

Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key to ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...